Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
|Slideshows|March 15, 2018
A New Tool for Springtime Mania
Author(s)Chris Aiken, MD
An environmental approach to mania makes it possible to “slow down the sun” and modulate the destabilizing effects of spring sunlight. More in this report.
Advertisement
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
2
Using Psychotherapy for the Prevention of Relapse in Schizophrenia
3
Searching for a New TMS Target in Schizophrenia, With Andrew Pines, MD
4
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
5